7894, ALZEDETECT, ISOREA: Blood test kit for Early Risk Detection of Alzheimer’s Disease
| Reference number | |
| Coordinator | Isorea AB |
| Funding from Vinnova | SEK 4 997 893 |
| Project duration | April 2025 - September 2027 |
| Status | Ongoing |
| Venture | Eurostars |
Purpose and goal
Over a decade of research at Karolinska Institutet, ISOREA has developed a breakthrough Early Alzheimer´s Disease (AD) Risk Detection Kit to predict the risk of AD development by diagnosing the Mild Cognitive Impairment (MCI) stage. This will help slowing the disease progression or even cure it by new drugs. Herein ISOREA aim to reduce the analysis time and increase the sensitivity of the Kit, for use by any blood testing clinics/hospitals. This will contribute to combating the AD pandemic.
Expected effects and result
Globally >55 million people are living with dementia (>60% AD), which estimated to become 152 million cases by 2050 - a true pandemic! AD progression can be slowed down or can be cured if detected early. Yet, today there are no affordable and accurate methods for early detection. In this project we aim to develop a new antibody for greater sensitivity and will also reduce the analysis time of our Kit, which can be used for mass screening of people at risk.
Planned approach and implementation
Our Eurostars project is divided into three work packages (WP). WP1 is for project management and dissemination of the results to wider audience. Herein, we aim to apply for a patent application from WP3 and to prepare a Quality Management System (QMS) document. WP2 is to improve our KIT´s sensitivity and specificity by method optimisation and to initiate the IVDR application for CE marking. WP3 is aim to develop new monoclonal antibody (new IP) for improving KIT’s specificity.